KRAS G12C-Mutant Non-Small-Cell Lung Adenocarcinoma: First Documented Report in the Arabian Gulf.

Autor:	Alsulaiman AS; Molecular Diagnostic Unit, Alhada Armed Forces Hospital, Taif, SAU., Alharthi SB; Molecular Diagnostic Unit, Alhada Armed Forces Hospital, Taif, SAU.; Biological Sciences, King Abdulaziz University, Jeddah, SAU., Albariqi AS; Molecular Diagnostic Unit, Alhada Armed Forces Hospital, Taif, SAU., Mutabaqani RA; Molecular Diagnostic Unit, Alhada Armed Forces Hospital, Taif, SAU., Bokhari FF; Academic Affairs, Directory of Armed Forces Hospitals, Taif, SAU., Tayeb IM; Biological Sciences, King Abdulaziz University, Jeddah, SAU., Alharthi DR; Physical Therapy Department, Alhada Armed Forces Hospital, Taif, SAU., Tariq MU; Histopathology Unit, Alhada Armed Forces Hospital, Taif, SAU., Babaier YH; Molecular Virology Unit, Alhada Armed Forces Hospital, Taif, SAU.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Jul 21; Vol. 14 (7), pp. e27090. Date of Electronic Publication: 2022 Jul 21 (Print Publication: 2022).
DOI:	10.7759/cureus.27090
Abstrakt:	We report the first documented case series of two lung adenocarcinoma patients demonstrating Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations by reverse transcription-polymerase chain reaction techniques from Saudi Arabia. Both patients were males aged 64 and 76 years. The first had a heavy smoking history, while the second did not report any history of smoking. The tumor subtype was identified to be non-mucinous lung adenocarcinoma in both cases. The younger patient presented with generalized lymphadenopathy and a right-sided lung mass lesion, while the older patient exhibited stage III-A left lung adenocarcinoma that required rapid response. An initial examination of the first case showed a right-sided mediastinal shift, bilateral neck lymphadenopathy, and poorly differentiated neoplasm from a right supraclavicular core biopsy, leading to treatment with palliatives along with regular checkups. The second case was afebrile after being confirmed to be vitally stable and laboratory testing (Neutr 100). Further studies, specifically on large numbers of patients from the Arabian Gulf, are needed to confirm significant differences between the national and international populations. Additionally, future studies should investigate more differences in the differentiation of KRAS-mutant lung adenocarcinoma between patients from the Arabian Gulf and others. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Alsulaiman et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu